Alterity Therapeutics (ATH) H2 2026 earnings summary

Executive summary

• Achieved a pivotal regulatory milestone with FDA alignment on Phase 3 trial design for ATH434 in Multiple System Atrophy (MSA), following positive Phase 2 results and manufacturing readiness for late-stage development.

• Ended FY2026 with A$37.3 million in cash, bolstered by a subsequent A$3.98 million R&D tax incentive refund, and completed a 1-for-50 share consolidation to optimize capital structure.

• Central operational objective for FY2027 is to initiate the Phase 3 trial of ATH434 in MSA, with trial activities expected to begin by year-end 2026.

Financial highlights

• Revenue from ordinary activities increased 284.7% year-over-year to A$1,716,656, primarily from interest income.

• Net loss after tax rose 92.6% year-over-year to A$23,400,949, reflecting increased R&D and administrative expenses.

• Research and development expenses grew 22% to A$17,629,577; general and administrative expenses increased 92% to A$10,528,013.

• Cash and cash equivalents at June 30, 2026 were A$37,317,962, up from A$33,158,642 the prior year.

• No dividends declared or paid for FY2026.

Outlook and guidance

• Preparations for Phase 3 ATH434 trial in MSA are underway, with initiation targeted by end of calendar 2026.

• Continued focus on capital management and strategic options, including potential partnerships and licensing.

• Ongoing evaluation of pipeline expansion and further development of platform technology for neurodegenerative diseases.